Free Trial

Alimera Sciences Q3 2023 Earnings Report

Alimera Sciences EPS Results

Actual EPS
-$0.06
Consensus EPS
-$0.41
Beat/Miss
Beat by +$0.35
One Year Ago EPS
N/A

Alimera Sciences Revenue Results

Actual Revenue
$23.36 million
Expected Revenue
$24.40 million
Beat/Miss
Missed by -$1.04 million
YoY Revenue Growth
N/A

Alimera Sciences Announcement Details

Quarter
Q3 2023
Time
N/A

Conference Call Resources

Conference Call Audio

This Indicator called BOTH NVDA rallies (Ad)

Rarely would I label something as “the best” But in this rare instance, I believe this is THE BEST indicator for trading Nvida’s stock. Except, it’s not another tech stock like Nvidia. But rather a stock hiding in broad daylight… So, if you’d like to see what this stock is…

Click this link here. 

Alimera Sciences Earnings Headlines

ANI Pharmaceuticals’ Record Growth and Strategic Acquisition
2025 AI Stock Picks: 2 Hidden Gems Under $10/Share
The AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months.
Alimera Sciences, Inc. (ALIM)
See More Alimera Sciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Alimera Sciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Alimera Sciences and other key companies, straight to your email.

About Alimera Sciences

Alimera Sciences (NASDAQ:ALIM), a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). It also provides YUTIQ, a fluocinolone acetonide intravitreal implant to treat NIU-PS. The company sells its products to physician offices, clinics, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. to develop, manufacture, and sell products including YUTIQ for the treatment and prevention of uveitis; and Ocumension (Hong Kong) Limited for the development and commercialization of the company's 190 microgram fluocinolone acetonide intravitreal implant in applicator for the treatment and prevention of eye diseases. Alimera Sciences, Inc. was incorporated in 2003 and is headquartered in Alpharetta, Georgia.

View Alimera Sciences Profile

More Earnings Resources from MarketBeat

Upcoming Earnings